BMB-101

Small molecule

Phase 2topline reported

Evidence outlook

Epilepsy: topline reported 2026-01-06

The sponsor reported topline results on 2026-01-06 (Phase 2 BREAKTHROUGH of BMB-101 reported positive topline results in absence seizures and DEE). The announcement is listed under Regulatory events.

Also in development:Developmental and Epileptic Encephalopathies · Phase 2Absence Seizures · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Developmental and Epileptic Encephalopathies
Other / comorbidity
NCT07266324 · Bright Minds Biosciences Pty Ltd
2026-01 – 2027-03 · Prader-Willi Syndrome
What this study did
Phase 1 (1)
Other / comorbidity
NCT05397041 · Bright Minds Biosciences Pty Ltd
2022-06-06 – 2023-05-04 · Healthy
What this study did

Competitive landscape

This drug's own stage for Absence Seizures: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
BMB-101: this drugPhase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow BMB-101 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Prader-Willi SyndromeNot yet recruiting
Est. primary completion 2026-11 · NCT07266324 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 January 2026Topline resultPhase 2 BREAKTHROUGH of BMB-101 reported positive topline results in absence seizures and DEE
Bright Minds Biosciences Inc. · Source ↗